EffRx Pharmaceuticals SA is a Swiss-based commercial-stage pharmaceutical company developing and commercializing prescription medications for specialty indications. The primary focus is on women and men health therapeutics for patients with musculoskeletal, genitourinary and endocrine disorders. The business model is centred at the creation of superior clinical and commercial value propositions for physicians, payers and patients. We strive to provide improved patient outcomes that address true unmet medical needs.
EffRx has an experienced management team with proven development and commercialization success in its primary therapeutic areas. EffRx has set up a global distribution-partnering model with established companies and is commercializing its products through companies that have a strong local footprint and sales force in place.
Our lead commercialized product, Binosto® (buffered effervescent alendronate 70mg for oral solution) was approved by the FDA to treat osteoporosis in 2012 and is also approved in Europe, MENA countries, Asia and Australia. The approval and commercial launch of Binosto® provides EffRx an important proof-of-concept for EffRx and highlights a number of potential advantages over traditional therapeutic approaches.
Our lead development product, EX404, targets polycystic ovary syndrome (PCOS) in adolescents. EffRx received an orphan drug designation (ODD) from FDA in 2014. EffRx has also an additional development program for an orphan liver indication in its pipeline.